



IMRICOR SUBMITS ADVANTAGE-MR® SYSTEM FOR FDA 510(K) CLEARANCE

06 February 2026 – Melbourne, Australia (**05 February 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** today announces that it has submitted its **Advantage-MR® EP Recorder/Stimulator** system for market clearance under the U.S. Food and Drug Administration’s (FDA’s) 510(k) premarket notification pathway.

The Advantage-MR system is an MR Conditional electrophysiology (EP) mapping system, used to acquire, amplify, filter, digitize, display, and record electrical signals obtained during electrophysiological studies and ablations. Signal types include intracardiac electrograms, as detected by diagnostic and ablation catheters inside the heart, along with surface ECG.

The Advantage-MR system also provides a hardware and software interface for MRI systems from Siemens and Philips, with GE coming soon, allowing the MRI systems to identify and utilize miniature tracking receive coils embedded in Imricor’s Vision-MR® catheters. The MRI systems then pass these tracking coil signals to Imricor’s NorthStar® for locating the catheters within the body.

The Advantage-MR system incorporates a programmable cardiac stimulator (pacemaker) for diagnostic cardiac stimulation during electrophysiological evaluations of the heart.

Imricor’s Chair and CEO, Steve Wedan, commented: “I often say that NorthStar is the central hub of our iCMR labs. In a similar way, the Advantage-MR system is the glue that brings all of the components of iCMR together, including the catheters, MRI systems, the ablation generator, the 12-lead ECG, and NorthStar.

We initially developed Advantage-MR because simply recording clean electrical signals from the heart is too challenging for any other EP recording system on the market, and none of them are safe for use in an MRI environment. There were also no MRI compatible external cardiac stimulators, so we integrated that functionality into Advantage-MR. Today’s Advantage-MR, however, not only provides EP recording and programmable cardiac stimulation in the MRI environment, it also connects all of the iCMR systems and devices to one another to create a complete and comprehensive iCMR lab solution. Advantage-MR represents decades of multiple 3rd party technical and business collaborations.”

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633



About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. US FDA approval is in process, and further approvals in other geographies such as Australia are being planned.

Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.